Sec Form 4 Filing - Hwang Kuk Hyoun @ Bellevue Life Sciences Acquisition Corp. - 2023-02-14

FORM 4 Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0287 Expires: November 30, 2011 Estimated average burden hours per response... 0.5

1. Name and Address of Reporting Person Hwang Kuk Hyoun 2. Issuer Name and Ticker or Trading Symbol Bellevue Life Sciences Acquisition Corp. [ BLAC] 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X __ Director X __ 10% Owner X __ Officer (give title below) _____ Other (specify below) Chief Executive Officer (Last) (First) (Middle) 10900 NE 4TH STREET, SUITE 2300 3. Date of Earliest Transaction (MM/DD/YY) 02/14/2023 (Street) BELLEVUE, WA98004 4. If Amendment, Date Original Filed (MM/DD/YY) 6. Individual or Joint/Group Filing (Check Applicable Line) __ X __ Form filed by One Reporting Person _____ Form filed by More than One Reporting Person (City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 1.Title of Security (Instr. 3) 2. Transaction Date (MM/DD/YY) 2A. Deemed Execution Date, if any (MM/DD/YY) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4) Code V Amount (A) or (D) Price Common Stock 02/14/2023 J( 2 ) 20,000 D ( 2 ) $ 0 1,705,000 ( 1 ) ( 2 ) I By Bellevue Global Life Sciences Investors LLC Common Stock 02/14/2023 J( 3 ) 20,000 D ( 3 ) $ 0 1,685,000 ( 1 ) ( 3 ) I By Bellevue Global Life Sciences Investors LLC Common Stock 02/14/2023 J( 4 ) 20,000 D ( 4 ) $ 0 1,665,000 ( 1 ) ( 4 ) I By Bellevue Global Life Sciences Investors LLC Common Stock 02/14/2023 J( 5 ) 20,000 D ( 5 ) $ 0 1,645,000 ( 1 ) ( 5 ) I By Bellevue Global Life Sciences Investors LLC Common Stock 02/14/2023 J( 6 ) 20,000 D ( 6 ) $ 0 1,625,000 ( 1 ) ( 6 ) I By Bellevue Global Life Sciences Investors LLC Common Stock 02/14/2023 J( 7 ) 225,000 D ( 7 ) $ 0 1,400,000 ( 1 ) ( 7 ) I By Bellevue Global Life Sciences Investors LLC Common Stock 02/14/2023 J( 8 ) 30,000 D ( 8 ) $ 0 1,370,000 ( 1 ) ( 8 ) I By Bellevue Global Life Sciences Investors LLC Common Stock 02/14/2023 A( 9 ) 430,000 A ( 9 ) $ 10 1,800,000 ( 1 ) ( 9 ) I By Bellevue Global Life Sciences Investors LLC

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities) 1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (MM/DD/YY) 3A. Deemed Execution Date, if any (MM/DD/YY) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) 6. Date Exercisable and Expiration Date (MM/DD/YY) 7. Title and Amount of Underlying Securities (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4) Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares Private Placement Warrants $ 11.5 02/14/2023 P 430,000 ( 10 ) ( 10 ) Common Stock ( 10 ) 430,000 ( 10 ) $ 10 430,000 ( 10 ) I By Bellevue Global Life Sciences Investors LLC Warrant for Common Stock $ 11.5 02/14/2023 J( 11 ) 20,000 ( 11 ) ( 11 ) Common Stock 20,000 $ 0 410,000 I By Bellevue Global Life Sciences Investors LLC Warrant for Common Stock $ 11.5 02/14/2023 J( 12 ) 20,000 ( 12 ) ( 12 ) Common Stock 20,000 $ 0 390,000 I By Bellevue Global Life Sciences Investors LLC

Reporting Owners Reporting Owner Name / Address Relationships Director 10% Owner Officer Other Hwang Kuk Hyoun 10900 NE 4TH STREET, SUITE 2300 BELLEVUE, WA98004 X X Chief Executive Officer Signatures /s/ Kuk Hyoun Hwang 02/16/2023 Signature of Reporting Person Date

Explanation of Responses:

( 1 )Represents shares of common stock held by Bellevue Global Life Sciences Investors LLC the sponsor of the Issuer (the "Sponsor"), whose general partner is Bellevue Capital Management LLC ("Bellevue Capital"). Kuk Hyoun Hwang is the managing partner of Bellevue Capital and has voting and dispositive power over the shares held by the Sponsor. ( 2 )Represents the shares transferred by the Sponsor to Mr. Jin Whan Park for his board service. ( 3 )Represents the shares transferred by the Sponsor to Mr. Steven Reed for his board service. ( 4 )Represents the shares transferred by the Sponsor to Mr. In Chul Chung for his board service. ( 5 )Represents the shares transferred by the Sponsor to Mr. Husun Euh for his board service. ( 6 )Represents the shares transferred by the Sponsor to Mr. Rad Roberts for his board service. ( 7 )Represents the shares that were forfeited as a result of the underwriters' not exercising their over-allotment option. ( 8 )Represents the shares transferred by the Sponsor to t he underwriters. ( 9 )The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. ( 10 )The Sponsor purchased an aggregate of 430,000 Private Placement Units at a price of $10.00 per Private Placement Unit in a private placement that occurred simultaneously with the consummation of the Issuer's Public Offering. Each Private Placement Unit consists of one share of Common Stock, one redeemable warrant entitling the holder to purchase one share of Common Stock, and one right which entitles the holder thereof to receive one-tenth (1/10) of a share of common stock. The Private Placement Warrants are exercisable only to purchase whole shares of Common Stock at an exercise price of $11.50 per share, subject to adjustments. Each warrant will become exercisable 30 days after the Issuer's Public Offering. Each warrant will expire five years after the completion of the Issuer's Public Offering, or earlier upon redemption or liquidation. ( 11 )Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Dr. In Chul Chung for his service as Chairman of the Audit Committee. ( 12 )Represents the warrant to purchase a total of 20,000 shares of the Issuer, transferred from the Sponsor to Mr. Steven Reed for his service as Chairman of the Board of Directors.

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.